Citadel Advisors’s Nanobiotix NBTX Stock Holding History

Citadel Advisors’s Portfolio NBTX Stock Details NBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-32,556	Closed	-$537K	–	13539
2020 Q4	$537K	Buy	+32,556	New	+$561K	﹤0.01%	8009

Other funds holding NBTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Citadel Advisors's NBTX Position: Q1 2021 in Review

Citadel Advisors sold out of Nanobiotix (NBTX) in Q1 2021, closing a stake of 32,556 shares — an estimated $537K sold.

Citadel Advisors first reported a position in NBTX in Q4 2020 and held it in 1 quarter. The position peaked at $537K in Q4 2020. 10 funds tracked by Wall St. Rank hold NBTX as of Q1 2021.

Citadel Advisors reported no remaining Nanobiotix position as of Q1 2021 after selling out during the quarter.
Citadel Advisors sold 32,556 Nanobiotix shares in Q1 2021, an estimated $537K.
Citadel Advisors first reported a position in Nanobiotix in Q4 2020 and held it in 1 quarter.
Citadel Advisors's Nanobiotix position peaked at $537K in Q4 2020.
10 funds tracked by Wall St. Rank held Nanobiotix as of Q1 2021.

Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.